Does Big Pharma need a modern day match-maker? With so many weak pipelines, the Fast Money traders think some could use a mate!
Following are the traders' perfect pairings.
Pfizer (PFE) should mate with Biogen (BIIB) for their blockbuster drugs. “It’s a match made in heaven,” Adami said.
Roche (ROG) should get fixed up with Genentech (DNA). “But that’s an easy one,” Finerman said, “because they’re already in bed together.”
Bristol Meyers (BMY) should hook-up with Imclone (IMCL). “They have a great cancer pipeline, why not buy them up?” Najarian exclaimed.
Pfizer (PFE) should make overtures for Celgene (CELG). In an homage to Gene Rayburn, the host of Match Game, Jeff Macke said, “Dylan, if they don’t acquire someone they’re going to be “blanked!!!!!”
Got something to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to .
Trader disclosure: On Oct 23, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (YHOO), (COH), (DIS), (EMC), Najarian Owns (SII), (C), (GOOG), (YHOO), Najarian Owns (AMZN) Options; Finerman Owns (C ), (GS), (BIIB), (BEAS), (MSFT); Finerman's Firm And Finerman Own (TGT); Finerman's Firm Owns (WMT), Finerman's Firm Owns Russell 2000 Puts; Finerman's Firm Owns S&P 500 Puts